Clinuvel Pharmaceuticals Ltd
CUVL · XNASCIK 1290877fmd_1PQ06HHEG1R4J06PFAGXVCW1METemplate: Standard
Coverage: Jul 01, 2023 to Jun 30, 2026, 3 periods
| Line item | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Total revenues | 58 | 61 | 64 |
| Cost of revenue | 11 | 12 | 11 |
| Gross profit | 47 | 50 | 53 |
| Research and development | 10 | 13 | 12 |
| Total operating expenses | 19 | 23 | 25 |
| Operating income | 29 | 27 | 28 |
| Interest and investment income | 5 | 6 | 7 |
| Other non-operating income (expense) | 0 | (0) | 0 |
| Income before taxes | 33 | 33 | 33 |
| Income tax expense | 10 | 10 | 10 |
| Net income from continuing operations | 23 | 23 | 23 |
| Net income | 23 | 23 | 23 |